OncoGenex Pharmaceuticals has announced the commencement of a fourth Phase II genitourinary (GU) cancer study, as part of its OGX-427 Overcoming Resistance in Cancer (ORCA) programme.

The Borealis-2 investigator-sponsored trial is a randomised, controlled Phase II study designed to assess OGX-427 in patients with advanced or metastatic bladder cancer, in whom disease has progressed after the initial platinum-based chemotherapy treatment.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Memorial Sloan-Kettering Cancer Center associate physician Jonathan Rosenberg said that when bladder cancer patients relapse, resistance to chemotherapy is common.

"The study will assess if OGX-427 and docetaxel combination therapy can improve survival compared to docetaxel alone."

"This trial will evaluate the potential of OGX-427 to work synergistically with second- or third-line chemotherapy to overcome treatment resistance and prolong survival in patients with advanced bladder cancer," Rosenberg said.

The study will assess if OGX-427 and docetaxel combination therapy can improve survival compared to docetaxel alone.

See Also:

OncoGenex president and chief executive officer Scott Cormack said; "The launch of Borealis-2 marks OncoGenex’ continued commitment to expanding the OGX-427 clinical development programme to better understand treatment resistance in GU cancers."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

OGX-427 is designed to restrain Heat Shock Protein 27 (HSP27), the over expression of which is believed to be a crucial factor for the development of treatment resistance, in addition to producing negative clinical outcomes in patients with various tumour types.

HSP27 is a cell-survival protein found at elevated levels in many human cancers such as prostate, bladder, breast and non-small cell lung cancer.